Martine A. Rothblatt Sells 1,269 Shares of United Therapeutics Corporation (UTHR) Stock
United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,269 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $118.04, for a total transaction of $149,792.76. Following the completion of the transaction, the chief executive officer now owns 1,409 shares in the company, valued at $166,318.36. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.01 by $2.26. The firm had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. United Therapeutics Corporation’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.23 earnings per share.
COPYRIGHT VIOLATION WARNING: “Martine A. Rothblatt Sells 1,269 Shares of United Therapeutics Corporation (UTHR) Stock” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/02/martine-a-rothblatt-sells-1269-shares-of-united-therapeutics-corporation-uthr-stock.html.
UTHR has been the topic of several recent analyst reports. ValuEngine upgraded shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. BidaskClub lowered shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Zacks Investment Research lowered shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. Finally, UBS AG reiterated a “sell” rating and issued a $106.00 target price on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Five equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $132.82.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Eagle Global Advisors LLC acquired a new position in shares of United Therapeutics Corporation during the second quarter worth $206,000. TLP Group LLC bought a new stake in shares of United Therapeutics Corporation in the second quarter worth $246,000. HPM Partners LLC increased its stake in shares of United Therapeutics Corporation by 0.8% in the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after buying an additional 15 shares during the last quarter. Fort L.P. increased its stake in shares of United Therapeutics Corporation by 5.2% in the second quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock worth $261,000 after buying an additional 99 shares during the last quarter. Finally, Prospera Financial Services Inc bought a new stake in shares of United Therapeutics Corporation in the second quarter worth $277,000.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.